We have chosen congenital TTP as a simple genetic disorder causing massively increased thrombotic risk and morbidity, but this approach could potentially be extended to the study of immuno‐mediated TTP, as it acts by circumventing the lack of ADAMTS‐13 functionality. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.